EDINA

PetVivo Reports Third Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Monday, February 12, 2024
Conference call, Expense, EDINA, Marketing, Average cost, Animal, Sale, MWI, Nine Months, Webcast, Three Months, Research, Cryptocurrency

EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).
  • “We are excited about the progress the Company has made this past quarter, including the addition of Covetrus North America, LLC.
  • (Covetrus), to distribute our products beginning in January 2024,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
  • Cost of sales were $183,087 and $223,687 for the three months ended December 31, 2023 and 2022, respectively.

PetVivo Reports Second Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Ethos, Sale, Webcast, Three Months, Research, ThinkEquity, Conference call, Clinical trial, Expense, Patient, Animal, Marketing, Pain, EDINA, Average cost, Quality of life, Limp, Total revenue, Cryptocurrency, Clothing, Pharmaceutical industry, Life insurance, Conference

EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).
  • Revenues were $207,366 and $223,280 for three months ended September 30, 2023 and 2022, respectively.
  • Cost of sales was $140,913 and $148,149 for the three months ended September 30, 2023 and 2022, respectively.
  • The weighted average number of shares outstanding was 12,325,973 and 10,021,090 for the six months ended September 30, 2023 and 2022, respectively.

PetVivo Reports First Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Total revenue, Abstract, Marketing, Conference call, Horse, Bank statement, Catalog, Sale, Distributor, Animal, Annual report, Dog, EDINA, Webcast, United, Cat, Pharmaceutical industry, Cryptocurrency, Life insurance, Conference

EDINA, MN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended June 30, 2023 (“first quarter of 2024”).

Key Points: 
  • Subsequent to June 30, 2023, the Company raised an aggregate of $2,325,000 in net proceeds from two offerings.
  • “Spryng™ is currently used by over 450 veterinarian clinics in 47 states in the United States”.
  • In the three months ended June 30, 2022, our revenues of $58,174 consisted entirely of sales to veterinary clinics.
  • Cost of sales were $82,269 and $53,020 for the three months ended June 30, 2023 and 2022, respectively.

PetVivo Reports Fiscal 2023 Full Year Financial Results

Retrieved on: 
Thursday, June 29, 2023
Total revenue, Standby Equity Distribution Agreement, MWI, Human, Anterior cruciate ligament injury, Paycheck Protection Program, Marketing, Conference call, Bank statement, Veterinarian, G&A, Research, Average cost, Sale, Trial of the century, Animal, Annual report, Dog, Distribution, EDINA, Webcast, Anterior cruciate ligament, Forgiveness, ACL, DVM, Tobacco, Vaccine, Pharmaceutical industry, Cryptocurrency, AmerisourceBergen, Conference

EDINA, MN, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for its fiscal year ended March 31, 2023 (“fiscal 2023”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for its fiscal year ended March 31, 2023 (“fiscal 2023”).
  • Revenues were $917,162 in fiscal 2023 compared to $115,586 for fiscal 2022.
  • Cost of sales was $526,817 in fiscal 2023 compared to $201,154 for fiscal 2022.
  • Operating expenses increased to $9,123,797 in fiscal 2023 compared to $4,970,960 in fiscal 2022.

PetVivo Reports Third Quarter of Fiscal 2023 Financial Results

Retrieved on: 
Thursday, February 9, 2023
Forgiveness, Marketing, Limp, DVM, Dog, Osteoarthritis, Horse, Marginal cost, Webcast, Conference call, Therapy, Animal, Sale, EDINA, PPP, MWI, Research, Pharmaceutical industry, Video game, Airline, Internet service provider, Conference

EDINA, MN , Feb. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the third quarter of fiscal 2023. The Company began commercialization of its lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021.

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN , Feb. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the third quarter of fiscal 2023.
  • John Lai, CEO, commented, “I’m excited about our team’s performance in the third quarter of fiscal 2023 highlighted by revenues of $510,109 as compared to $51,004 in the same period a year ago.
  • Product shipments to MWI increased to $456,502 in the third quarter as compared to $118,264 in the second quarter of 2023.
  • In January 2023, we entered into a lease agreement for approximately 14,000 square feet of production and warehouse space in Edina, Minnesota.

PetVivo Reports Second Quarter of Fiscal 2023 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Marginal cost, Forward-looking statement, Dog, Marketing, Method, U.S. Securities and Exchange Commission, Disclosure, Expense, Nasdaq, Webcast, Horse, Research, Private Securities Litigation Reform Act, EDINA, Sale, Investor relations, Conference call, Intermediary, MWI, SEC, Regulation Fair Disclosure, PPP, Forgiveness, Company, Limp, CEO, Therapy, Animal, Security (finance), Regulation, Standby Equity Distribution Agreement, Osteoarthritis, Pharmaceutical industry, Medical device, Airline, Life insurance, Reinsurance, Income, Conference

EDINA, MN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (“PetVivo” or the “Company”) (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the second quarter of fiscal year 2023. The Company began commercialization of its lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses, in September 2021.

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (PetVivo or the Company) (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the second quarter of fiscal year 2023.
  • John Lai, CEO, commented, I am excited to report that we began shipping our products to MWI in the second quarter of fiscal 2023 pursuant to our Distribution Agreement.
  • Revenues were $223,280 for the three months ended September 30, 2022 compared to revenues of $4,977 for the three months ended September 30, 2021.
  • Cost of sales was $148,159 and $0 for the three months ended September 30, 2022 and 2021, respectively.

PetVivo Reports First Quarter of Fiscal 2023 Financial Results

Retrieved on: 
Thursday, August 11, 2022
U.S. Securities and Exchange Commission, Disclosure, Veterinarian, Osteoarthritis, Income, EDINA, Investor relations, Industry, CEO, GLOBE, Forward-looking statement, Regulation Fair Disclosure, SEC, Dog, Sale, Conference call, Security (finance), Research, Method, Marketing, Patient, Company, Therapy, Paycheck Protection Program, Webcast, Private Securities Litigation Reform Act, Nasdaq, Forgiveness, Animal, Regulation, MWI, Horse, Medical device, Video game, Pharmaceutical industry, Life insurance, Conference

EDINA, MN, Aug. 11, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the first quarter of fiscal 2023.

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Aug. 11, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the first quarter of fiscal 2023.
  • This new relationship will benefit the industry, the veterinarians who provide medical care, their patients, and pet owners alike.
  • Revenue was $58,174 and $4,145 for three months ended June 30, 2022 and 2021, respectively, and consisted of Spryng sales to veterinary clinics.
  • The Company increased its inventory to $180,874 as of June 30, 2022 in order to support its expected revenue growth in 2023.

PetVivo to Discuss Financial Results for the Fiscal Year End ended March 31, 2022 and Business Update

Retrieved on: 
Wednesday, June 29, 2022
Horse, G&A, Research, Expense, MWI, GLOBE, Conference call, Marketing, Sale, EDINA, Company, U.S. Securities and Exchange Commission, Regulation Fair Disclosure, Forward-looking statement, Multichannel Multipoint Distribution Service, Disclosure, Therapy, Total revenue, Forgiveness, Nasdaq, Marginal cost, Investor relations, SEC, Dog, Limp, Animal, Private Securities Litigation Reform Act, Regulation, Paycheck Protection Program, Webcast, Osteoarthritis, Security (finance), Method, Medical device, Online gambling, Spice, Pharmaceutical industry, Risk management, Income, Conference

EDINA, MN, June 29, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for its fiscal year ended March 31, 2022.

Key Points: 
  • Fiscal Year Ended March 31, 2022 (fiscal 2022) Compared to The Year Ended March 31, 2021 (fiscal 2021)
    Total Revenues.
  • Revenues increased to $115,586 in fiscal 2022 compared to $12,578 in fiscal 2021 and consisted of sales to veterinary clinics.
  • Cost of sales was $201,154 in fiscal 2022 compared to $10,695 for fiscal 2021.
  • Operating expenses increased to $4,970,960 in fiscal 2022 compared to $1,960,871 in fiscal 2021.

PetVivo Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, February 10, 2022
Income, Regulation, Webcast, Regulation Fair Disclosure, Company, G&A, SEC, Animal, Dog, Nasdaq, Therapy, Method, Disclosure, Paycheck Protection Program, Forgiveness, Sale, Horse, Marketing, EDINA, Osteoarthritis, Investor relations, GLOBE, Conference call, Video game, Airline, Life insurance, Pharmaceutical industry, Conference

EDINA, MN, Feb. 10, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three and nine months ended December 31, 2021.

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Feb. 10, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three and nine months ended December 31, 2021.
  • Highlights from the third quarter of 2022 and recent weeks include the following:
    The most significant event on our financial results during the last quarter results from the commercialization and sale of our primary product, Spryng, to veterinary clinics.
  • We ended our first full quarter following the commencement of sales of Spryng with $51,004 in revenue.
  • General and administrative (G&A) expenses increased to $1,170,870 for the three months ended December 31, 2021 compared to $331,148 for the three months ended December 31, 2020.

PetVivo Reports Second Quarter 2022 Financial Results - Updated

Retrieved on: 
Monday, November 15, 2021
Paycheck Protection Program, Regulation Fair Disclosure, Investor relations, Method, Password, Income, EDINA, Dog, Animal, ID, Conference call, Osteoarthritis, Sale, Horse, Company, Research, GLOBE, Disclosure, Therapy, SEC, Webcast, Marketing, Forgiveness, Regulation, Pharmaceutical industry

EDINA, MN, Nov. 15, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three and six months ended September 30, 2021.

Key Points: 
  • Cost of sales was $-0- and $350 for the three months ended September 30, 2021 and 2020, respectively.
  • General and administrative expenses were $756,186 and $787,427 for the three months ended September 30, 2021 and 2020, respectively.
  • Sales and marketing expenses were $235,767 and $35,580 for the three months ended September 30, 2021 and 2020, respectively.
  • Research and development expenses were $116,380 and $ -0- for the three months ended September 30, 2021 and 2020, respectively.